Home / About Novasep / Media & Events / Press releases

Press releases

Novasep adds synthesis and kilo lab extensions to US facility

28 Jan 2016

Enhanced capabilities bring Novasep’s unique range of specialized drug development technologies within easier reach of North American customers


Novasep and Advanced Biotherapeutics Consulting team up on Adeno-Associated Virus (AAV) vectors

Novasep and Advanced Biotherapeutics Consulting team up on Adeno-Associated Virus (AAV) vectors

13 Jan 2016

Strategic partnership creates a world leading CDMO offer to supply AAV-based viral vectors, an increasingly attractive therapeutic platform for gene therapy


Novasep and CPI advance innovation in UK biopharmaceutical manufacturing

10 Nov 2015

Novasep’s BioSC® Lab continuous biochromatography equipment will enable CPI to disseminate next-generation downstream processes


Novasep appoints world-class scientists to strengthen its advisory board

29 Sep 2015

Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep


Novasep invests €10M to reinforce its bioconjugation services

25 Jun 2015

Expansion marks Novasep’s readiness for full range Antibody Drug Conjugates CMO services


Novasep launches BioSCĀ® Lab, next-generation biochromatography equipment for protein purification in batch and continuous modes

Novasep launches BioSC® Lab, next-generation biochromatography equipment for protein purification in batch and continuous modes

15 Jun 2015

Simulation software BioSC® PredictTM enables instant switch from batch to continuous modes

Winner of Achema 2015 Innovation Award


Novasep signs two deals to further develop its presence in Japan

08 Jun 2015

Allied Laboratories and AR Brown selected as local agents


Novasep appoints two executives to further strengthen its management team

05 May 2015

Pierre-Louis Mikus joins as chief legal officer; Bertrand Waymel is promoted to group human resources director


Novasep reports strong 2014 full year results

21 Apr 2015

- Swift execution of ‘Back to Basics’ strategic plan leading to successful portfolio reshaping
- All business units contributing to the strong performance
- 20% EBITDA growth driven by focus on attractive projects and cost control policy


Novasep and Celladon Execute MYDICAR API supply agreement

24 Mar 2015

Pompey, France, and San Diego, CA, USA, March 24, 2015 - Novasep, a leading supplier of services and technologies for the life sciences and chemical industries and Celladon Corporation (Nasdaq:CLDN), a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.


You can continue visiting and select more documents or directly download the one you selected.